Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Kalaris Therapeutics (KLRS) Net Income towards Common Stockholders (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Net Income towards Common Stockholders data on record, last reported at -$25.3 million in Q4 2020.

  • For Q4 2020, Net Income towards Common Stockholders fell 189.25% year-over-year to -$25.3 million; the TTM value through Dec 2020 reached -$69.9 million, changed N/A, while the annual FY2024 figure was -$58.8 million, 69.14% up from the prior year.
  • Net Income towards Common Stockholders reached -$25.3 million in Q4 2020 per KLRS's latest filing, down from -$23.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$7.3 million in Q3 2019 and bottomed at -$25.3 million in Q4 2020.